Endometrial hyperplasia with atypia is an overgrowth of the uterine lining in which the cells have begun to look abnormal under a microscope. It is classified as a precancerous condition, with a 20% to 50% chance of progressing to uterine cancer if left untreated. That risk is what separates it sharply from ordinary endometrial hyperplasia, which rarely becomes cancerous. If you’ve received this diagnosis, here’s what it means, why it happens, and what the path forward typically looks like.
How It Differs From Hyperplasia Without Atypia
The uterine lining, or endometrium, naturally thickens and sheds each menstrual cycle. In endometrial hyperplasia, that lining grows too thick. Pathologists currently divide this into two categories: hyperplasia without atypia, which is considered benign, and atypical hyperplasia, which is precancerous. This two-category system was adopted by the World Health Organization in 2014 and is now the standard worldwide.
The word “atypia” refers to what the cells look like under a microscope. In atypical hyperplasia, the cells have abnormal nuclei (irregular in size and shape) and a disorganized structural arrangement. These features signal that the cells are behaving in ways that move them closer to cancer. You may also see this condition called “endometrial intraepithelial neoplasia” or EIN, which is the preferred term in some guidelines. They describe the same thing.
Why It Develops
The central driver is prolonged exposure to estrogen without enough progesterone to counterbalance it. In a normal cycle, estrogen thickens the uterine lining in the first half, and progesterone stabilizes it in the second half. When that balance tips toward estrogen, the lining keeps growing unchecked.
Obesity is one of the strongest risk factors, and the biology is straightforward. Fat tissue acts as an estrogen-producing organ. It contains an enzyme that converts other hormones into estrogen, and the more fat tissue you carry, the more estrogen your body produces. In addition to this hormonal effect, obesity drives insulin resistance, which activates cell-growth pathways in the uterine lining independently. Chronic low-grade inflammation from excess fat tissue adds a third layer of risk. These three mechanisms, estrogen overproduction, insulin resistance, and inflammation, work together to push endometrial cells toward abnormal growth.
Other situations that create estrogen dominance include not ovulating regularly (common in polycystic ovary syndrome), taking estrogen-only hormone therapy without progesterone, late menopause, and certain estrogen-producing ovarian tumors. Tamoxifen, used in breast cancer treatment, also acts like estrogen on the uterine lining and raises risk.
Symptoms to Recognize
The most common sign is abnormal uterine bleeding. What that looks like depends on where you are in life. Before menopause, it typically shows up as heavier-than-normal periods, bleeding between periods, or cycles that become irregular or unpredictable. After menopause, any vaginal bleeding is considered abnormal and warrants investigation. Some people also experience periods with clots or bleeding that lasts longer than usual. There are no pain symptoms specific to hyperplasia itself, so bleeding is often the only clue.
How It’s Diagnosed
Diagnosis requires a tissue sample from the uterine lining, examined under a microscope by a pathologist. The most common first step is an office-based endometrial biopsy, which uses a thin, flexible tube inserted through the cervix to collect a small sample. This procedure takes only a few minutes and doesn’t require anesthesia, though it can cause cramping.
Studies show that office biopsy has excellent accuracy for detecting hyperplasia, with 100% sensitivity and specificity for this diagnosis compared to the more involved dilation and curettage (D&C) procedure. A D&C, performed under sedation, collects a larger and more comprehensive tissue sample and may be recommended if the office biopsy is inconclusive or if there’s a concern that a small biopsy could miss something. Transvaginal ultrasound is often used as a first screening tool to measure lining thickness, but it cannot distinguish between types of hyperplasia or detect atypia. Only a biopsy can do that.
The Link to Uterine Cancer
This is the part of the diagnosis that understandably causes the most anxiety. Atypical hyperplasia is a direct precursor to type I endometrial cancer, the most common form. Without treatment, 20% to 50% of cases will progress to cancer, influenced by factors like the degree of cellular abnormality and underlying genetic changes.
There’s another statistic worth understanding. In large studies of women diagnosed with atypical hyperplasia on biopsy who then had a hysterectomy, about 30% to 40% already had cancer present in the uterus at the time of surgery. In one study of 629 women, 30.7% were found to have concurrent endometrial cancer at hysterectomy. This doesn’t mean the biopsy was wrong. It means that a biopsy samples only a small portion of the lining, and cancer can coexist in areas that weren’t sampled. This high rate of concurrent cancer is one of the main reasons surgery is strongly recommended.
Surgical Treatment
Hysterectomy (removal of the uterus) is the definitive treatment. The American College of Obstetricians and Gynecologists is clear on this point: it is the standard of care for atypical hyperplasia. Importantly, it must be a total hysterectomy, meaning the cervix is removed along with the uterus. A supracervical hysterectomy, which leaves the cervix in place, is specifically advised against because atypical tissue can extend into the lower uterine segment or upper cervix.
Endometrial ablation, a procedure that destroys the uterine lining using heat or electrical energy, is also not appropriate. It has high rates of persistence and recurrence, and it can make it difficult to evaluate any future bleeding that might signal a problem.
Most hysterectomies for this condition are performed minimally invasively (laparoscopic or robotic), which typically means a hospital stay of one to two days and a recovery period of several weeks. The removed uterus is examined by a pathologist, which is when any concurrent cancer would be identified and staged.
Fertility-Sparing Options
For younger people who want to preserve the ability to become pregnant, hormonal treatment with high-dose progestins is an alternative, though it carries real tradeoffs. The most commonly used medications are oral progestins taken daily. A progestin-releasing intrauterine device (IUD) is sometimes used alone or alongside oral medication. The IUD delivers a higher concentration of progestin directly to the uterine lining while causing fewer systemic side effects like weight gain, blood clot risk, mood changes, and headaches.
Fertility-sparing treatment is not a permanent solution. It aims to reverse the abnormal changes long enough to achieve pregnancy, after which hysterectomy is typically recommended. Close monitoring is essential during this approach, with repeat endometrial biopsies every three to six months to check whether the lining has returned to normal. Guidelines recommend at least two consecutive negative biopsies, taken six months apart, before a patient can be considered in remission. Even then, recurrence is common, and long-term annual surveillance is advised for anyone at higher risk.
The response rates to progestin therapy vary, and not all cases of atypical hyperplasia will reverse. If the condition persists or recurs after treatment, hysterectomy becomes the recommended next step regardless of fertility goals.
Long-Term Monitoring After Treatment
After hysterectomy, the risk of endometrial hyperplasia is eliminated because the uterus has been removed. If cancer was found in the surgical specimen, follow-up will depend on the stage and type.
For those managed with progestin therapy, ongoing surveillance is critical. Biopsies are typically performed every three to six months during treatment and for a period after successful regression. Women with persistent risk factors like obesity, ongoing estrogen exposure, or a history of recurrence may need annual biopsies indefinitely. Addressing modifiable risk factors, particularly weight management, plays a meaningful role in reducing the chance of recurrence.